Eszter Lazar-Molnar, PhD, D(ABMLI)

Languages

  • English

Academic Information

  • Departments: Pathology - Assistant Professor (Clinical)
  • Divisions: Clinical Pathology

Board Certification

  • American Board of Histocompatibility & Immunogenetics
  • American Board of Medical Laboratory Immunology

Academic Office Information

  • 801-583-2787-Ext-3674
  • ARUP
    500 Chipeta Way
    Salt Lake City, UT 84108

Email: eszter.lazar-molnar@path.utah.edu

Education History

Type School Degree
Fellowship University of Utah
Immunology
Clinical Fellow
Postdoctoral Fellowship Albert Einstein College of Medicine
Microbiology & Immunology
Postdoctoral Fellow
Research Fellow Cancer Research Institute
Postdoctoral Research Fellow
Doctoral Training Semmelweis University School of Medicine
Genetics, Cell and Immunobiology
Ph.D.
Residency Iuliu Hatieganu University of Medicine and Pharmacy
Pharmacy
Resident
Doctoral Training University of Medicine and Pharmacy of Târgu Mureș
Pharmacy
Pharm.D.

Global Impact

Education History

Type School Degree Country
Doctoral Training Semmelweis University School of Medicine
Genetics, Cell and Immunobiology
Ph.D. Hungary
Residency Iuliu Hatieganu University of Medicine and Pharmacy
Pharmacy
Resident Romania
Doctoral Training University of Medicine and Pharmacy of Târgu Mureș
Pharmacy
Pharm.D. Romania

Selected Publications

Journal Article

  1. Pavlov IY, Parker RL, Lazar-Molnar E, Strathmann FG, Delgado JC (2019 Apr 26). Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum.LID - S0022-1759(19)30027-4 [pii]LID - 10.1016/j.jim.2019.04.008 [doi]. (Epub ahead of print) J Immunol Methods.
  2. Yang Y, Wysocki E, Antwi K, Niederkofler E, Leung EKY, Lazar-Molnar E, Yeo KJ (2018 Aug). Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clin Chim Acta, 483, 308-314.
  3. Willrich Maria Alice V, Lazar-Molnar Eszter, Snyder Melissa R, Delgado Julio C (). Comparison of clinical laboratory assays for measuring serum infliximab and antibodies for infliximab. J Appl Lab Med, 2(6), 893-903.
  4. Profaizer T, Lazar-Molnar E, Pole A, Delgado JC, Kumanovics A (2017 Aug). HLA genotyping using the Illumina HLA TruSight next-generation sequencing kits: A comparison. Int J Immunogenet, 44(4), 164-168.
  5. Lazar-Molnar E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, Ramagopal UA, Nathenson SG, Guha C, Almo SC (2017 Mar). Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine, 17, 30-44.
  6. Profaizer T, Lazar-Molnar E, Close DW, Delgado JC, Kumanovics A (2016 Jul). HLA genotyping in the clinical laboratory: comparison of next-generation sequencing methods. HLA, 88(1-2), 14-24.
  7. Pavlov IY, Carper J, Lazar-Molnar E, Delgado JC (2016 Jan 30). Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clin Chim Acta, 453, 147-53.
  8. Scandiuzzi L, Ghosh K, Hofmeyer KA, Abadi YM, Lazar-Molnar E, Lin EY, Liu Q, Jeon H, Almo SC, Chen L, Nathenson SG, Zang X (2014 Feb 27). Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Rep, 6(4), 625-32.
  9. Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan S, Carreno LJ, Venkataswamy MM, Kim J, Lazar-Molnar E, Lauvau G, Chang YT, Liu Z, Bittman R, Al-Shamkhani A, Cox LR, Jervis PJ, Veerapen N, Besra GS, Porcelli SA (2014 Jan 16). A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity, 40(1), 105-16.
  10. Vigdorovich V, Ramagopal UA, Lazar-Molnar E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo SC (2013 May 7). Structure and T cell inhibition properties of B7 family member, B7-H3. Structure, 21(5), 707-17.
  11. Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, Porcelli SA, Almo SC, Nathenson SG, Jacobs WR Jr (2010 Jul 27). Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A, 107(30), 13402-7.
  12. Lazar-Molnar E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC (2008 Jul 29). Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A, 105(30), 10483-8.
  13. Shi L, Albuquerque PC, Lazar-Molnar E, Wang X, Santambrogio L, Gacser A, Nosanchuk JD (2008 Jul). A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages. Eukaryot Cell, 7(7), 1109-17.
  14. Lazar-Molnar E, Gacser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD (2008 Feb 19). The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A, 105(7), 2658-63.
  15. Lazar-Molnar E, Almo SC, Nathenson SG (2006 Dec). The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function. Cell Immunol, 244(2), 125-9.
  16. Lazar-Molnar E, Hegyesi H, Pallinger E, Kovacs P, Toth S, Fitzsimons C, Cricco G, Martin G, Bergoc R, Darvas Z, Rivera ES, Falus A (2002 Oct). Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur J Clin Invest, 32(10), 743-9.
  17. Szincsak N, Hegyesi H, Hunyadi J, Martin G, Lazar-Molnar E, Kovacs P, Rivera E, Falus A, Juhasz I (2002 Jun). Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line. Melanoma Res, 12(3), 231-40.
  18. Horvath BV, Falus A, Toth S, Szalai C, Lazar-Molnar E, Holub MC, Buzas E, Nagy A, Fulop AK (2002 Mar 1). Inverse regulation of interleukin-6 (IL-6) and IL-6 receptor in histamine deficient histidine decarboxylase-knock-out mice. Immunol Lett, 80(3), 151-4.
  19. Fitzsimons CP, Lazar-Molnar E, Tomoskozi Z, Buzas E, Rivera ES, Falus A (2001 Nov 16). Histamine deficiency induces tissue-specific down-regulation of histamine H2 receptor expression in histidine decarboxylase knockout mice. FEBS Lett, 508(2), 245-8.
  20. Hegyesi H, Somlai B, Varga VL, Toth G, Kovacs P, Molnar EL, Laszlo V, Karpati S, Rivera E, Falus A, Darvas Z (2001 Jul). Suppression of melanoma cell proliferation by histidine decarboxylase specific antisense oligonucleotides. J Invest Dermatol, 117(1), 151-3.
  21. Molnar EL, Cricco G, Martin G, Darvas Z, Hegyesi H, Fitzsimons C, Bergoc R, Falus A, Rivera E (2001 Apr). Histamine as a potential autocrine regulator of melanoma. Inflamm Res, 50 Suppl 2, S102-3.
  22. Igaz P, Novk I, Lazar E, Horvth B, Hninger E, Falus A (). Bidirectional communication between histamine and cytokines. Inflamm Res, 20, 123-128.
  23. Horvath B, Heninger E, Hegyesi H, Lazar E, Radvany Z, Szalai C, Darvas Z, Falus A (2000 Apr). Reciprocal inhibitory interactions between interferon gamma and histamine in melanoma. Inflamm Res, 49 Suppl 1, S27-8.
  24. Kohidai L, Kovacs P, Lazar-Molnar E, Csaba G (2000). Presence, uptake and localization of an immunoreactively interleukin 6 (IL-6)-like molecule in Tetrahymena pyriformis. Cell Biol Int, 24(10), 749-55.
  25. Eugene V Ravkov, Cheryl M Charlton, Erik R Kish-Trier, Adam P Barker, Marc Couturier, Julio C Delgado, Harry Hill, Lisa K Peterson, Patricia Slev, Anne Tebo, Karl V Voelkerding, Carl Wittwer, Nahla Heikal, Eszter Lzr-Molnr, Attila Kumnovics (). Evaluation of Mass Cytometry in the Clinical Laboratory. Cytometry B Clin Cytom.

Review

  1. Lazar-Molnar E, Delgado JC (2019 Mar). Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. [Review]. Clin Chem, 65(3), 393-405.
  2. Lazar-Molnar E, Snyder M (2018 Dec). The Role of Human Leukocyte Antigen in Celiac Disease Diagnostics. [Review]. Clin Lab Med, 38(4), 655-668.
  3. Lzr-Molnr E, Delgado JC (). Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. [Review]. Clin Chem, 62(9), 1186-98.
  4. Lazar-Molnar E, Tebo AE (). Autoimmune NMDA receptor encephalitis. [Review]. Clin Chim Acta, 438, 90-7.
  5. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015 Jan). Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. [Review]. Trends Mol Med, 21(1), 24-33.
  6. Chattopadhyay K, Lazar-Molnar E, Yan Q, Rubinstein R, Zhan C, Vigdorovich V, Ramagopal UA, Bonanno J, Nathenson SG, Almo SC (2009 May). Sequence, structure, function, immunity: structural genomics of costimulation. [Review]. Immunol Rev, 229(1), 356-86.
  7. Falus A, Hegyesi H, Lazar-Molnar E, Pos Z, Laszlo V, Darvas Z (2001 Dec). Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. [Review]. Trends Immunol, 22(12), 648-52.
  8. Lazar-Molnar E, Hegyesi H, Toth S, Falus A (2000 Jun). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. [Review]. Cytokine, 12(6), 547-54.
  9. Molnar EL, Hegyesi H, Toth S, Darvas Z, Laszlo V, Szalai C, Falus A (2000 Feb). Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. [Review]. Semin Cancer Biol, 10(1), 25-8.

Book Chapter

  1. Lazar-Molnar E (). Signal-transduction pathways of histamine receptors. In Falus A (Ed.), Histamine: Biology and Medical Aspects. Budapest: SpringMed Publishing Ltd.

Case Report

  1. Lazar-Molnar E, Kumanovics A (). Immunodeficiency evaluation in adults with recurrent bacterial infections. ASCP LabQ, 1605(2016).

Editorial

  1. Delgado JC, Lazar-Molnar E (2018 Dec). HLA in Transplantation and Beyond. Clin Lab Med, 38(4), xi-xii.

Abstract

  1. Profaizer T, Pole A, Monds C, Kumanovics A, Delgado JC, Lazar-Molnar E (). HLA Disease Association Testing by NGS. Is it superior to other methods? [Abstract]. Human Immunology, 79, Supplement 1(October), 121.
  2. Profaizer T, Margraf RL, Delgado JC, Lazar-Molnar E, Kumanovics A (). Developing an assay to detect and quantify donor-derivevd DNA in the blood and urine of solid organ transplant recipients [Abstract]. Human Immunology, 79, Supplement 1(October), 146.
  3. Profaizer T, Ellinger L, Krishnakumar S, Tamse Kuehn R, Delgado J, Lazar-Molnar E (). Class II haplotypes associated with DRB1*12 using full gene sequence analysis by next generation sequencing [Abstract]. Human Immunology, 78, Supplement 1(October), 197.
  4. Pole A, Delgado JC, Lazar-Molnar E (). Impact of the new kidney allocation system on highly sensitized recipient transplant rates: The Utah experience [Abstract]. Human Immunology, 77 Supplement, 52.
  5. Lazar-Molnar E, Andersen EF, Profaizer T, Pole A, Taylor MR, Delgado JC (). Resolution of conflicting HLA assignment due to loss of heterozygosity in the HLA region by NGS typing [Abstract]. Human Immunology, 77 Supplement, 28.
  6. Profaizer T, Lazar-Molnar E, Delgado JC, Kumanovics A (). Comparison of four HLA next-generation sequencing typing methods [Abstract]. Human Immunology, 77 Supplement, 105.
  7. Profaizer T, Lazar-Molnar E, Delgado J, Kumanocis A (). Experience using the illumina HLA trusight NGS kits: Version 1 vs. version 2 [Abstract]. Human Immunology, 77 Supplement, 94.
  8. Lazar-Molnar E, Hurst D, Pole A, Delgado JC (). Residual serum rituximab induces false positive flow cytometric B cell crossmatch more than 6 months post-infusion [Abstract]. Human Immunology, 76 Supplement, 128.
  9. Lazar-Molnar E, Spruit L, Pole A, Williams K, Taylor MR, Delgado JC (). The effect of pronase on lymphocyte surface markers and implications for flow cytometric crossmatch [Abstract]. Human Immunology, 76 Supplement, 131.
  10. Profaizer T, Lazar-Molnar E, Delgado JC, Kumanovics A (). Comparing fragment size with read-length and their effect on HLA genotyping by next-generation sequencing (NGS) [Abstract]. Human Immunology, 76 Supplement, 52.
  11. Lazar-Molnar E, Chen B, Jacobs WR, Nathenson S (). Inhibition through PD-1 is crucial for protection against M. tuberculosis infection; abstract also presented at the 98th Annual Meeting of the American Association of Immunologists, San Francisco, CA [Abstract]. Journal of Immunology, 186(58), 1.
  12. Lazar-Molnar E, Ramagopal U, Almo S, Nathenson S (). Structural and functional studies on PD-1: from crystals to mice; abstract also presented at the 98th Annual Meeting of the American Association of Immunologists, San Francsico, CA [Abstract]. Journal of Immunology, 186(63), 17.
  13. Lazar-Molnar E, Chen B, Almo SC, Jacobs WR Jr, Nathenson SG (). The role of Programmed Death-1 (PD-1) in pulmonary M. tuberculosis infection: friend or foe?; abstract also presented at the 97th Annual Meeting of the American Association of Immunologists, Baltimore, MD [Abstract]. Journal of Immunology, 184(40), 10.
  14. Lazar-Molnar E, Gacser A, Nosanchuk JD, Freeman G, Almo SC, Nathenson SG (). The PD-1/PD-L costimulatory pathway plays a key role in Histoplasma capsulatum pathogenesis; abstract also presented at the 94th Annual Meeting of the American Association of Immunologists, Miami Beach, FL [Abstract]. Journal of Immunology, 178, B122.

Newspaper

  1. DeArment Alaric (). Agenus' GBM vaccine Prophage sparks expert optimism about PD-1 inhibitor combination possibility. BioPharm Insight.

Video/Film/CD/Web/Podcast

  1. Lazar-Molnar E (). Immunogenicity testing for TNF antagonists in the clinical laboratory [Video]. Pearls in Laboratory Medicine. Clinical Chemistry Trainee Council.